A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

Metastatic Breast Cancer

Part 1: AEs, SAEs, DLTs, laboratory findings, Part 2: AEs, SAEs, laboratory findings

Part 2: ORR defined as the proportion of patients who have a confirmed CR or PR, as determined by the investigator at local site per RECIST 1.1, Part 2: PFS defined as time from the date of first dose until the date of progression as determined by the investigator at local site per RECIST 1.1, or death due to any cause, Part 2: DoR defined as time from the date of first documented response (which is subsequently confirmed) until the date of documented progression or death in the absence of disease progression, Part 2: OS defined as time from the date of first dose until the date of death by any cause, Serum concentration of T-DXd, total anti-HER2 antibody and MAAA- 1181a, Serum concentration of durvalumab, Immunogenicity of T-DXd and durvalumab

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Belgium